ArticleProstate cancer and prostatic diseases2021
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.Communications medicine · 2026Article
- Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.Nature cancer · 2026Article
- Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.Journal of the National Cancer Institute · 2024Article
- Article
- Risk factor control and incident cardiovascular disease in patients with diabetes: Sex-specific relations.Diabetes, obesity & metabolism · 2024Article
- Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.Journal of the National Cancer Institute · 2023Article
- PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.BMC cancer · 2022Article
- Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations.European urology open science · 2022Article
- Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations.Journal of Alzheimer's disease : JAD · 2022Article
- Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention.Medical review (2021) · 2021Review
- Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.Prostate cancer and prostatic diseases · 2021Article
- KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
71 authors at 20 institutions in 18 countries.
Roshan A KarunamuniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. rakarunamuni@health.ucsd.edu.ORCID http://orcid.org/0000-0001-8723-8123
Minh-Phuong Huynh-LeRadiation Oncology, George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-5025-4709
Chun C FanCenter for Human Development, University of California San Diego, La Jolla, CA, USA.
Wesley ThompsonDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA.
Rosalind A EelesThe Institute of Cancer Research, London, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-3698-6241
Zsofia Kote-JaraiThe Institute of Cancer Research, London, SM2 5NG, UK.
Kenneth MuirDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0001-6429-988X
Artitaya LophatananonDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
UKGPCS collaborators
Johanna SchleutkerInstitute of Biomedicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-1863-0305
Nora PashayanDepartment of Applied Health Research, University College London, London, WC1E 7HB, UK.
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, 4059, Australia.ORCID http://orcid.org/0000-0003-4646-6247
APCB BioResource (Australian Prostate Cancer BioResource)
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77, Stockholm, Sweden.
Eleanor I WalshBristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK.
Emma L TurnerBristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK.
Athene LaneBristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK.
Richard M MartinBristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-7992-7719
David E NealNuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
Børge G NordestgaardFaculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Robert J MacInnisCancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC, 3004, Australia.
Alicja WolkUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Christopher A HaimanCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90015, USA.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA.
Catharine M L WestDivision of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, M13 9PL, UK.
Sune F NielsenFaculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.
Adam S KibelDivision of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4623-0544
Olivier CussenotSorbonne Universite, GRC n°5, AP-HP, Tenon Hospital, 4 rue de la Chine, F-75020, Paris, France.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Stella KoutrosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Karina Dalsgaard SørensenDepartment of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200, Aarhus, Denmark.ORCID http://orcid.org/0000-0002-4902-5490
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115, Szczecin, Poland.
Eli Marie GrindedalDepartment of Medical Genetics, Oslo University Hospital, 0424, Oslo, Norway.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0002-6384-6447
Sue A InglesDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, 90015, USA.
Christiane MaierHumangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076, Tuebingen, Germany.
Robert J HamiltonDept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Barry S RosensteinDepartment of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Ana VegaFundación Pública Galega Medicina Xenómica, Santiago de Compostela, 15706, Spain.
IMPACT Study Steering Committee and Collaborators
Manolis KogevinasISGlobal, Barcelona, Spain.
Kathryn L PenneyChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 02184, USA.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072, Porto, Portugal.ORCID http://orcid.org/0000-0002-4896-5982
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany.
Esther M JohnDepartments of Epidemiology & Population Health and of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94304, USA.
Radka KanevaMolecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431, Sofia, Bulgaria.
Christopher J LogothetisThe University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA.
Azad RazackDepartment of Surgery, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.
Lisa F NewcombDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Canary PASS Investigators
Marija GamulinDivision of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, 10000, Zagreb, Croatia.ORCID http://orcid.org/0000-0003-2431-7910
Nawaid UsmaniDepartment of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, AB, T6G 1Z2, Canada.
Frank ClaessensMolecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU, Leuven, BE-3000, Belgium.
Manuela Gago-DominguezGenomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de Compostela, Spain.
Paul A TownsendDivision of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, Univeristy of Manchester, M13 9WL, Manchester, UK.
Monique J RoobolDepartment of Urology, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6967-1708
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN, 37232, USA.
Profile Study Steering Committee
Ian G MillsCenter for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
Ole A AndreassenNORMENT, KG Jebsen Centre, Oslo University Hospital and University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-4461-3568
Anders M DaleDepartment of Radiology, University of California San Diego, La Jolla, CA, USA.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. tseibert@ucsd.edu.ORCID http://orcid.org/0000-0002-4089-7399
PRACTICAL Consortium
University of California San Diego · USBrigham and Women's Hospital · USOslo University Hospital · NOUniversity of Southern California · USManchester Academic Health Science Centre · GBUniversity of Cambridge · GBUniversity of Copenhagen · DKAarhus University · DKInstitute of Cancer Research · GBKarolinska Institutet · SEQueen's University Belfast · GBRoyal Marsden NHS Foundation Trust · GBThe University of Texas MD Anderson Cancer Center · USTranslational Research Institute · AUUniversidade do Porto · PTUniversitat Pompeu Fabra · ESUniversity Hospital Centre Zagreb · HRUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Alberta · CAUniversity of Bristol · GB
Funding
SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MPCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchU01CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2019 to 2023
$5.4MImproving assessment of prostate cancer bone metastases using advanced diffusion imagingK08EB026503 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SEIBERT, TYLER MICHAEL · 2019 to 2022
$805kCancer Research UK 15064Cancer Research UK 19169Cancer Research UK 24432Cancer Research UK 29017Cancer Research UK 29019Medical Research Council G0500966Medical Research Council MR/M012190/1NCI NIH HHS U01 CA182883NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NIBIB NIH HHS K08 EB026503
Abstract
backgroundPolygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46). MATERIALS AND
method180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.
results166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.
conclusionsIncorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.
Indexed as
Models, StatisticalPolymorphism, Single NucleotideAdultAgedBiomarkers, TumorFollow-Up StudiesHumansMaleMiddle AgedPredictive Value of TestsPrognosisProstatic NeoplasmsRisk AssessmentRisk FactorsBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01221168ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.